A TRIAL OF EXEMESTANE IN POSTMENOPAUSAL WOMEN WITH DCIS OR AT HIGH RISK FOR INVA

对患有 DCIS 或 INVA 高风险的绝经后妇女进行依西美坦试验

• 批准号: 7952008
• 负责人: Claudine Isaacs
• 金额: $ 3.11万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7952008
• 关键词: BRCA1 gene; BRCA2 Mutation; Biological Markers; Biopsy; Bone Density; Breast; Breast Cancer Risk Assessment Tool; Chemoprevention; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Exemestane; Funding; Grant; Hormones; Institution; Leptin; Lesion; Lipids; Mammary Gland Parenchyma; Mammographic Density; Noninfiltrating Intraductal Carcinoma; Phase II Clinical Trials; Postmenopause; Prolactin; Prolactin Receptor; Recording of previous events; Research; Research Personnel; Resources; Risk; Serum; Source; Staging; United States National Institutes of Health; Woman; high risk; lobular breast carcinoma in situ; malignant breast neoplasm; open label

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is an investigator-initiated open label phase II clinical trial examining the use of exemestane as a chemoprevention for breast cancer among high risk, post-menopausal women. High risk is defined as: history of stage I or II breast cancer 2 years out from definitive therapy; Gail model 5 year risk ? 1.7%; history of treated DCIS; history of high risk lesion on breast biopsy (ADH, ALH, LCIS); or known or suspected BRCA1 or BRCA2 mutation. The primary objective is to determine the effect of exemestane on mammographic density after one year of therapy. Secondary objectives include determining the effect of exemestane on: bone mineral density, breast tissue biomarkers (mammotome biopsy annually for 2 years is required; markers include TFF-1, PCNA, prolactin , prolactin receptor), and modulations of serum biomarkers (hormones, leptin, IGF components, lipids).

这个子项目是众多研究子项目之一